Topical Cyclosporine A in the Prevention of Pterygium Recurrence

Tök, Özlem; Nurözler, Ayşe Burcu; Ergun, Gul; Kocaoğlu, Fatma Akbaş; Duman, Sunay

doi:10.1159/000151740

Cited by 34 publications

(18 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our recurrence rate was 06% in the Cyclosporine group, which was more than the recurrence observed by Aydin et al 18 . (3.4%), but lower than observed by Tok et al (12.9%) 17 . It may be higher than observed by Aydin et al because of the study population of only vascularized and recurrent pterygium, which is more prone for higher recurrence compared to primary pterygium 20 .…”

Section: Pak J Ophthalmolcontrasting

confidence: 52%

See 1 more Smart Citation

Role of Topical Cyclosporine in Prevention of Pterygium Recurrence, after Primary Excision

Ahmed¹

2019

pak J Ophthalmol

View full text Add to dashboard Cite

Purpose: To study the effect of cyclosporine on pterygium recurrence after primary excision Study Design: Non randomized controlled trial. Place and Duration of Study: The study was conducted in the department of Ophthalmology, Liaquat University of Medical and Health Sciences, Jamshoro from 2015 to 2017. Material and Methods: One hundred and thirty eyes of 65 patients having bilateral pterygium, at least 2 mm encroaching on the cornea, were selected for study. Dimensions of pterygium were measured on slit lamp. Half of the eyes were selected for post-operative cyclosporine and was named as cyclo- eye and fellow other eye was named as non-cyclo eye. Immediate post-operative treatment was tobramycin dexamethasone eye ointment twice and moxifloxacin eye drops three times daily until corneal epithelium was restored, followed by moxifloxacin and Cyclosporine eye drops twice daily until complete healing of ocular surface occurred and then cyclosporine 0.05% alone once daily in the evening up to three months. In the fellow eye tobramycin dexamethasone eye ointment and moxifloxacin eye drops were used for complete healing time followed by tears alone three times for three months. Follow up was done for six months. Results: Only Fifty-three patients who completed 6 months of follow-up were included in the results. In cyclo-eyes recurrent pterygium was observed only in 4 (07.55%) and in non-cyclo eyes recurrence was observed in 23 (43.40%) eyes. Mean healing time in cyclo-eyes was 21.1354 days and in non-cyclo-eyes, 15.0213 days. Conclusion: Cyclosporine is effective in reducing the recurrence rate of pterygium. Key Words: Pterygium, Cyclosporine, Cornea.

show abstract

Section: Pak J Ophthalmolcontrasting

confidence: 52%

“…Pterygia on the temporal side are rare and should be differentiated from squamous cell tumor. Double-headed pterygium, is very rare, only 2.5% 17 .…”

Section: Pak J Ophthalmolmentioning

confidence: 99%

Role of Topical Cyclosporine in Prevention of Pterygium Recurrence, after Primary Excision

Ahmed¹

2019

pak J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The first-line treatment for pterygium is surgical excision, but recurrence is the most common complication [63]. CsA, an anti-inflammatory agent, has been administered topically to treat a variety of inflammatory disorders of the ocular surface [60].…”

Section: Discussionmentioning

confidence: 99%

“…CsA prevents the activation and nuclear translocation of cytoplasmic transcription factors that are required for T-helper cell activation and inflammatory cytokine production [62]. Importantly, topical application of CsA prevents pterygium recurrence [63–66]. A previous study suggested that CsA treatment of the residual conjunctiva after pterygium excision may block the activation and proliferation of pterygium fibroblasts [25].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13

et al. 2017

View full text Add to dashboard Cite

We examined the connection between matrix metalloproteinase (MMP) expression/activity and pterygium fibroblast migration, and how these were affected by bevacizumab and/or cyclosporine A (CsA). Fibroblasts were obtained from 20 pterygia and 6 normal conjunctival specimens. Expression levels of MMP-3 and MMP-13 were examined after bevacizumab administration. Immunofluorescence staining was used to examine expression of both MMPs in fibroblasts migrating out from explanted pterygium tissues. Rates of cell migration from explant-cultured pterygia tissues and scratch-wounded confluent pterygium fibroblasts were examined in the presence of MMP-3 or MMP-13 inhibitors, as well as bevacizumab and/or CsA. A scratch wound healing migration assay was performed to determine the effects of bevacizumab and/or CsA. Protein expression of both MMPs in pterygium tissues and in cells migrating from organ-cultured pterygium tissues was greater than that observed in normal cells. Inhibition of the activities of both MMPs decreased their expression levels; these were also significantly reduced in bevacizumab-injected pterygium tissues. Bevacizumab significantly reduced the expression of both MMPs and cell migration. Pretreatment with CsA prior to bevacizumab exposure markedly inhibited cell migration and the expression of both MMPs. CsA enhanced the inhibitory effects of bevacizumab on pterygium fibroblast migration in vitro, possibly by inhibiting expression of both MMPs. These findings suggest that combined CsA and bevacizumab treatment may provide a potential therapeutic strategy for reducing the rate of pterygium recurrence.

show abstract

“…Tok et al used CsA following primary excision in primary pterygium cases, and the recurrence rate was determined to be 12.9% 25. In a study by Aydin et al, CsA was found to be effective in reducing recurrence and preventing postoperative pain and complications 26.…”

Section: Discussionmentioning

confidence: 99%

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery

Vural¹,

Torun-Acar²,

Kıvanç³

et al. 2011

OPTH

View full text Add to dashboard Cite

Purpose:To investigate the role of postoperative topical 0.05% cyclosporine A (CsA) eye drops (Restasis®, Allergan Pharmaceutical) in the prevention of recurrence among patients with primary pterygium treated with bare-sclera technique.Methods:In this prospective randomized controlled study, 36 eyes (34 patients) with primary pterygium were randomized into two groups: Group I comprised 18 eyes (18 patients), and Group II comprised 18 eyes (16 patients). Bare sclera technique was performed in both groups. In Group I, 0.05% CsA was administered postoperatively at 6-hour intervals for 6 months, and Group II did not receive any cyclosporine treatment. The patients were assessed for recurrence, side effects, and complications at postoperative 1 and 7 days as well as each month during the following year. Conjunctival advances which showed a limbus higher than 1 mm were recognized as recurrence.Results:Recurrence occurred in four patients (22.2%) in Group I and in eight (44.4%) patients in Group II.Conclusion:Postoperative application of low-dose CsA can be effective for preventing recurrences after primary pterygium surgery.

show abstract

Topical Cyclosporine A in the Prevention of Pterygium Recurrence

Cited by 34 publications

References 78 publications

Role of Topical Cyclosporine in Prevention of Pterygium Recurrence, after Primary Excision

Role of Topical Cyclosporine in Prevention of Pterygium Recurrence, after Primary Excision

Inhibition of Pterygium Fibroblast Migration and Outgrowth by Bevacizumab and Cyclosporine A Involves Down-Regulation of Matrix Metalloproteinases-3 and -13

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery

Contact Info

Product

Resources

About